The Predictive Role of Serum Levels of Soluble Cell Adhesion Molecules (sCAMs) in the Therapy of Advanced Breast Cancer-A Single-Centre Study

Soluble cell adhesion molecules (sCAMs) play a significant role in the metastatic potential of breast cancer (BC). They might block lymphocytes and promote angiogenesis and migration of cancer cells. We assessed the usefulness of sCAMs in the prognosis and monitoring of the progression of advanced B...

Full description

Saved in:
Bibliographic Details
Published in:Medicina (Kaunas, Lithuania) Lithuania), 2022-01, Vol.58 (2), p.153
Main Authors: Bulska-Będkowska, Weronika, Czajka-Francuz, Paulina, Jurek-Cisoń, Sylwia, Owczarek, Aleksander J, Francuz, Tomasz, Chudek, Jerzy
Format: Article
Language:English
Subjects:
Biomarkers
Blood pressure
Breast cancer
Breast Neoplasms - drug therapy
Cancer therapies
Cell adhesion & migration
Cell Adhesion Molecules
Chemotherapy
Diabetes
Disease
Endocrine therapy
Female
Fraud
Glycoproteins
Humans
Hypertension
Metastasis
Normal distribution
overall survival
Prognosis
progression-free survival
Software
soluble cell adhesion molecules
Tomography
Tumor necrosis factor-TNF
Tumors
Variance analysis
Vascular Cell Adhesion Molecule-1 - metabolism
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soluble cell adhesion molecules (sCAMs) play a significant role in the metastatic potential of breast cancer (BC). They might block lymphocytes and promote angiogenesis and migration of cancer cells. We assessed the usefulness of sCAMs in the prognosis and monitoring of the progression of advanced BC. We assessed soluble E-selectin, P-selectin, VCAM-1, ICAM-1, EpCAM, IL-6Ra, TNF-R1, and TNF-R2 in 39 women with aBC. Blood samples were obtained at the beginning of the treatment and after 2 months. The median progression-free survival (PFS) was 9 months, and overall survival (OS) was 27 months. The higher levels of sICAM-1 (HR = 2.60, = 0.06) and lower levels of sEpCAM (HR = 2.72, < 0.05) were associated with faster progression of aBC. High levels of sEpCAM through the follow-up period were significantly associated with a lower risk of progression (HR = 0.40, < 0.01). We found the independent predictive value of higher than median sICAM-1 levels for PFS (HR = 2.07, = 0.08) and of sVCAM-1 levels for OS (HR = 2.59, < 0.05). Our data support the predictive value of sICAM-1 and sVCAM-1 and suggest that they could become markers for tailoring new therapies in aBC. sEpCAM level could be used as an early indicator of response to the therapy.
ISSN:1648-9144
1010-660X
1648-9144
DOI:10.3390/medicina58020153